News & Events

Disc Medicine Announces Completion of Merger with Gemini Therapeutics

The combined company will operate as Disc Medicine and will trade on the Nasdaq Global Market under the ticker symbol “IRON” Approximately $175 million of cash and cash equivalents to provide operating runway into 2025 WATERTOWN, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) — Disc Medicine, Inc.

More News

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous...


read more

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

WATERTOWN, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...


read more

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...


read more